XPH:NYE-SPDR® S&P Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 46.29

Change

-0.87 (-1.84)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-14 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-2.31 (-1.57%)

USD 40.46B
FHLC Fidelity® MSCI Health Care In..

-1.17 (-1.67%)

USD 2.91B
FXH First Trust Health Care AlphaD..

-2.16 (-1.94%)

USD 1.19B
XHE SPDR® S&P Health Care Equipme..

-1.78 (-1.96%)

USD 0.22B
IDNA iShares Genomics Immunology an..

-0.66 (-2.70%)

USD 0.15B
SBIO ALPS Medical Breakthroughs ETF

-1.18 (-2.93%)

USD 0.13B
XHS SPDR® S&P Health Care Service..

-2.68 (-2.80%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.79 (-2.68%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

-1.78 (-2.73%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.93 (-3.17%)

USD 0.01B

ETFs Containing XPH

INAV 10.31 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.22% 86% B+ 59% D-
Dividend Return 1.26% 94% A 24% F
Total Return 12.48% 86% B+ 54% F
Trailing 12 Months  
Capital Gain 27.94% 81% B- 72% C
Dividend Return 1.93% 100% F 27% F
Total Return 29.87% 81% B- 71% C-
Trailing 5 Years  
Capital Gain 19.40% 33% F 57% F
Dividend Return 6.41% 67% D+ 17% F
Total Return 25.81% 38% F 48% F
Average Annual (5 Year Horizon)  
Capital Gain -1.38% 14% F 27% F
Dividend Return -0.70% 14% F 19% F
Total Return 0.68% 68% D+ 17% F
Risk Return Profile  
Volatility (Standard Deviation) 15.91% 67% D+ 65% D
Risk Adjusted Return -4.39% 10% F 20% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.